Burt Zweigenhaft, PhD, DLitt, is a key industry thought leader and accomplished executive within the specialty-biotech pharmaceutical and oncology cancer care ecosystems. Over the last 20 years Burt has incubated and launched specialty bio-pharmaceuticals with industry leaders the likes of Genzyme, Pharmacyclics, Gilead, Janssen, Pfizer, Alexion, Bayer, GSK, Seattle Genetics, Sanofi, Monogram Science, Roche, Genentech, CureVax, Genomic Health, Janssen and numerous emerging biotech incubators. He currently is the co-founder and executive director of The Association for Value-Based Cancer Care (AVBCC) and Managing Partner at Upstream Partners.